Respiratory syncytial virus (RSV) causes seasonal acute respiratory illness significantly impacting vulnerable groups, including lung transplant recipients (LTRs), who are at increased risk of hospitalization, acute rejection, and allograft dysfunction. The immunogenicity of the novel RSV Prefusion F3 (RSVPreF3-AS01, Arexvy, GlaxoSmithKline) vaccine in immunocompromised patients remains largely unknown. In this study, we assessed both antibody using and cellular immune responses two months after a single dose of the RSVPreF3-AS01 vaccine in 30 LTRs aged 60 years or older, who were at least six months post-transplant. The antibody response was assessed using enzyme-linked immuno sorbent assay for detection of serum anti RSV-F IgG specific antibodies, and the CD4+ T-cell response was measured by flow cytometry intracellular cytokine secretion assay. Our findings show that all vaccinees exhibited a CD4+ T-cell response two months post-vaccination, while only 40% demonstrated an antibody response. These results suggest that some patients may derive clinical benefit from the vaccine through cellular immunity, even without an antibody response. Furthermore, the vaccine was well tolerated in this vulnerable population, with no major safety concerns observed.
Keywords: Lung transplantation; RSV vaccine; Respiratory syncytial virus; T-cell response; antibody response; immunogenicity.
Copyright © 2025. Published by Elsevier Inc.